Suppr超能文献

噻嗪类药物对特发性高钙尿症儿童骨密度的影响。

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria.

机构信息

Pediatric Nephrology Department, Hospital Nuestra Señora de Candelaria, Carretera del Rosario nº 145, 38010, Santa Cruz de Tenerife, Canary Islands, Spain.

出版信息

Pediatr Nephrol. 2012 Feb;27(2):261-8. doi: 10.1007/s00467-011-1987-6. Epub 2011 Aug 28.

Abstract

To determine the effect of thiazide treatment on bone mineral density (BMD) in children with idiopathic hypercalciuria (IH) and osteopenia, we reviewed the case notes of 22 children aged 11.7 ± 2.7 years diagnosed with IH and osteopenia who had received thiazides for 2.4 years. The data on this group were compared with those of 32 IH children with osteopenia aged 11.2 ± 2.7 years who had not received thiazide treatment. By the end of the follow-up period, the z-BMD had improved spontaneously in 23 of the 32 control children (72%) and in 12 of the 22 patients on thiazides (54%). Although treated patients had a higher body mass index (BMI) and a higher BMD following treatment, the differences became statistically negligible when these parameters were expressed as z-BMD or as bone mineral apparent density (BMAD). In contrast, within the control group, there were significant differences in BMAD and z-BMD at the end of the follow-up. Patients who had an improved z-BMD at the end of the treatment also showed an increase in their BMI. Based on these results, we conclude that thiazide treatment does not improve the z-BMD in children with IH. More than half of the children suffering from IH enrolled in our study showed a spontaneous improvement in their z-BMD, which was more evident when the initial BMAD was not low and when their BMI increased during the follow-up period.

摘要

为了确定噻嗪类药物治疗对特发性高钙尿症(IH)和骨质疏松症儿童骨密度(BMD)的影响,我们回顾了 22 名年龄为 11.7±2.7 岁、诊断为 IH 和骨质疏松症并接受噻嗪类药物治疗 2.4 年的儿童的病历。将该组数据与未接受噻嗪类药物治疗的 32 名年龄为 11.2±2.7 岁、IH 合并骨质疏松症的儿童的数据进行了比较。在随访期末,32 名对照儿童中有 23 名(72%)和 22 名噻嗪类药物治疗组儿童中的 12 名(54%)自发改善了 z-BMD。尽管治疗组的体重指数(BMI)和治疗后 BMD较高,但当这些参数以 z-BMD 或骨矿物质表观密度(BMAD)表示时,差异具有统计学意义。相比之下,在对照组中,随访期末的 BMAD 和 z-BMD 存在显著差异。在治疗结束时 z-BMD 改善的患者其 BMI 也有所增加。基于这些结果,我们得出结论,噻嗪类药物治疗不能改善 IH 儿童的 z-BMD。我们研究中超过一半的 IH 患儿 z-BMD 自发改善,当初始 BMAD 不低且随访期间 BMI 增加时,这种改善更为明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验